A large Phase 3 trial combining the PATCH and STAMPEDE-1 networks, published in the New England Journal of Medicine, shows that transdermal estradiol patches are as effective as standard injections for treating locally advanced prostate cancer. The study found that three-year metastasis-free survival was similar between the two treatments, with 87.1% for the patch group […]
New results show that gotistobart outperforms standard chemotherapy docetaxel in patients with advanced squamous non-small cell lung cancer who have already failed prior immunotherapy. The study found that gotistobart achieved a much higher response rate, with 20% of patients showing tumor shrinkage compared to just 4.8% with docetaxel. Patients treated with gotistobart also lived longer,
Gotistobart Shows Stronger Results Than Chemotherapy in Advanced Squamous NSCLC Read More »
China’s National Medical Products Administration has granted conditional approval to a new pre-surgery treatment for adults with HER2-positive stage II or III breast cancer. The regimen uses trastuzumab deruxtecan followed by a combination of paclitaxel, trastuzumab, and pertuzumab, marking the first time this drug has been approved globally in the neoadjuvant setting. The decision is
The European Medicines Agency has approved a major update for subcutaneous daratumumab, allowing it to become the first cancer injectable in Europe that patients can administer themselves at home. This change means that patients with multiple myeloma, or their caregivers, can give the treatment outside of a hospital starting from the fifth dose, as long
EMA Approves First At-Home Self-Administration of Daratumumab in Europe Read More »
Japan’s Ministry of Health, Labour and Welfare has approved risovalisib for patients with advanced or recurrent ovarian clear cell carcinoma who carry PIK3CA mutations and whose disease has progressed after chemotherapy. The decision offers a new targeted option for a difficult-to-treat form of ovarian cancer. Alongside the drug, the AmoyDx PIK3CA Mutation Detection Kit was
Japan Approves Risovalisib for PIK3CA-Mutated Ovarian Clear Cell Carcinoma Read More »
A new study reveals why PARP inhibitors—targeted drugs used in ovarian cancer—work well for some patients but fail in others. Using advanced imaging of live human tumor samples, researchers found that the key difference lies in how these drugs spread and behave inside individual cancer cells. The study shows that some PARP inhibitors, such as
Uneven Drug Distribution Inside Cancer Cells May Explain PARP Inhibitor Resistance Read More »
New research highlights DNA methylation, a reversible epigenetic change, as a key factor in pancreatic ductal adenocarcinoma (PDAC) development, diagnosis, and treatment. In PDAC, tumor suppressor genes like p16 and E-cadherin are often “switched off” through hypermethylation, while oncogenes such as S100P and Maspin become abnormally active due to global hypomethylation, driving tumor growth and
DNA Methylation Emerges as Key Target for Pancreatic Cancer Diagnosis and Therapy Read More »
Interim results from a Phase 2b trial show that RAD 101 may help doctors distinguish true brain tumor recurrence from treatment-related changes. In a study of 30 patients with previously treated brain metastases, RAD 101 PET scans matched biopsy or clinical follow-up results in 90% of cases, demonstrating high accuracy. RAD 101 works differently from
RAD 101 PET Scan Shows High Accuracy in Detecting Brain Tumor Recurrence Read More »
Theriva Biologics has finalized a Phase 3 trial plan with the FDA to test zabilugene almadenorepvec combined with standard chemotherapy as a first-line treatment for metastatic pancreatic cancer. The trial follows promising Phase 2b results in 96 patients, which showed improved outcomes compared with chemotherapy alone: overall survival increased to 10.8 months versus 8.6 months,
The ICESECRET clinical trial shows that the ProSense Cryoablation System is a safe and effective treatment for small kidney tumors. In the study of 114 patients with localized tumors 5 cm or smaller, 83.9% remained free of recurrence after a median follow-up of four years. The procedure is minimally invasive and performed under CT guidance.
ProSense Cryoablation Shows Long-Term Success for Small Kidney Tumors Read More »